• 1
    Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002; 47: 47188.
  • 2
    Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 35362.
  • 3
    De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 2000; 39: 8597.
  • 4
    Peppercorn MA, Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 1973; 64: 2405.
  • 5
    Nielsen OH, Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol 1983; 16: 73840.
  • 6
    Schröder H, Campbell DES. Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972; 13: 53951.
  • 7
    Hardy JG, Healey JNC, Reynolds JR. Evaluation of an enteric-coated, delayed release 5-ASA tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 27380.
  • 8
    Hvidberg EF. GI tract conditions and topical/systemic availability of 5-aminosalicylic acid in a slow release preparation (Pentasa®). Acta Pharmacol Toxicol 1986; 59(Suppl. 5): 206.
  • 9
    Digenis GA, Sandefer EP, Parr AF, et al. Gastrointestinal behavior of orally administered radiolabelled erythromycin pellets in man as determined by gamma scintigraphy. J Clin Pharmacol Ther 1991; 5: 6975.
  • 10
    Hardy JG, Lamont GL, Evans DF, Haga AK, Gamst ON. Evaluation of an enteric-coated naproxen pellet formulation. Aliment Pharmacol Ther 1991; 5: 6975.
  • 11
    Hardy JG, Harvey WJ, Sparrow RA, et al. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa®) in the gastrointestinal tract using gamma scintigraphy. J Clin Pharmacol 1993; 33: 7128.
  • 12
    Davis SS, Hardy JG, Newman SP, Wilding IR. Gamma scintigraphy in the evaluation of pharmaceutical dosage forms. Eur J Nucl Med 1992; 19: 97186.
  • 13
    Krevsky B, Malmud LS, D'Ecrole F, Maurer AH, Fisher RS. Colonic transit scintigraphy — a physiologic approach to the quantitative measurement of colonic transit in humans. Gastroenterology 1986; 91: 110212.
  • 14
    Parr AF, Beihn R, Franz RM, Szpunar GJ, Jay M. Correlation of ibuprofen bioavailability with gastrointestinal transit by scintigraphic monitoring of 171Er labelled sustained-release tablets. Pharm Res 1987; 4: 4869.
  • 15
    Wilding IR, Hardy JG, Maccari M, Ravelli V, Davis SS. Scintigraphic and pharmacokinetic assessment of a multiparticulate sustained release formulation of diltiazem. Int J Pharm 1991; 76: 13343.
  • 16
    Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed release formulation. Pharm Res 1992; 9: 6547.
  • 17
    Brendel E, Meineke I, Witsch D, Zschunke M. Simultaneous determination of 5-aminosalicylic acid and 5-acetylaminosalicylic acid by high-performance liquid chromatography. J Chromatogr 1987; 385: 299304.
  • 18
    Fischer C, Maier K, Klotz U. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine. J Chromatogr 1981; 225: 498503.
  • 19
    Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe D'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993; 104: 4359.
  • 20
    Kruis W, Bar Meir S, Feher J, Stolte M. Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology 2000; 118: A780(Abstract).
  • 21
    Rasmussen HH, Jacobsen BA, Fallingborg J, Christensen LA, Abildgaard K , Rasmussen SN. Palatability of pentasa slow release preparation. Scand J Gastroenterol 1997; 32(Suppl. 224): F34.
  • 22
    Zhou SY, Fleisher D, Pao LH, Li C, Winward B, Zimmermann EM. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999; 27: 47985.
  • 23
    Staerk Laursen L, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 12716.
  • 24
    Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1987; 1: 27380.
  • 25
    Hardy JG, Healey JN, Lee SW, Reynolds JR. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Aliment Pharmacol Ther 1987; 1: 20916.
  • 26
    Goebell H, Klotz U, Nehlsen B, Layer P. Oroileal transit of slow release 5-aminosalicylic acid. Gut 1993; 34: 66975.
  • 27
    Layer PH, Goebell H, Keller J, Dignass A, Klotz U. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology 1995; 108: 142733.
  • 28
    Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37: 2932.
  • 29
    Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993; 104: 1293301.